Provident fund assets up 11.3%

October saw a positive gross nominal yield of 0.33% - up from 0.12% last October.

By DANIEL KENNEMER
December 6, 2005 07:52

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Provident fund assets grew by 11.3% since the beginning of the year to NIS 232 billion in October, the Finance Ministry said Monday. Net provident and mutual fund cumulation was positive in October, totalling NIS 232 million, up from NIS 179m. in September, and triple the NIS 79m. in positive cumulation registered in October 2004, the ministry said. Similarly, the positive cumulation in the funds totalled NIS 952m. since the beginning of the year, against NIS 357m. for the same period last year. October saw a positive gross nominal yield of 0.33% - up from 0.12% last October, while the cumulative yield for the first 10 months of the year totalled 12.08% - up from 5.12% last year.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS